Long-term cardiovascular risk in transplantation - Insights from the use of everolimus in heart transplantation

Nephrology Dialysis Transplantation

Volumn 21, Issue SUPPL. 3, 2006, Pages

  Eisen, Howard ^a  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Azathioprine; Cardiac allograft vasculopathy; Everolimus; Heart transplantation; MACE; Renal transplantation

Indexed keywords

AZATHIOPRINE; CREATININE; CYCLOSPORIN A; EVEROLIMUS; STEROID;

ACUTE HEART INFARCTION; ARTERY INTIMA PROLIFERATION; ARTICLE; CARDIAC GRAFT REJECTION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CREATININE BLOOD LEVEL; DEATH; DEFIBRILLATOR; DISEASE SEVERITY; DRUG COST; DRUG DOSE REGIMEN; DRUG TREATMENT FAILURE; FOLLOW UP; GRAFT FAILURE; GRAFT RECIPIENT; GRAFT SURVIVAL; HEART TRANSPLANTATION; HOSPITAL COST; HUMAN; INCIDENCE; INTRAVASCULAR ULTRASOUND; KIDNEY TRANSPLANTATION; LONG TERM CARE; MAJOR CLINICAL STUDY; MORBIDITY; MORTALITY; NEPHROTOXICITY; PERCUTANEOUS CORONARY INTERVENTION; PERIPHERAL VASCULAR DISEASE; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VASCULAR DISEASE;

AZATHIOPRINE; CARDIOVASCULAR DISEASES; CYCLOSPORINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; GLUCOCORTICOIDS; GRAFT REJECTION; HEART TRANSPLANTATION; HOSPITAL COSTS; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSIVE AGENTS; PENNSYLVANIA; POSTOPERATIVE COMPLICATIONS; RISK FACTORS; SIROLIMUS; TUNICA INTIMA;

EID: 33745767702     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfl295     Document Type: Article

References (26)

1. Schuler W, Sedrani R, Cottens S et al. SDZ RAD, a new rapamycin derivative. Pharmacological properties in vitro and in vivo. Transplantation 1997; 64: 36-42
2. Cao W, Mohacsi P, Shorthouse R, Pratt R, Morris RE. Effects of rapamycin on growth factor-stimulated vascular smooth muscle cell DNA synthesis. Inhibition of basic fibroblast growth factor and platelet-derived growth factor action and antagonism of rapamycin by FK506. Transplantation 1995; 59: 390-395
3. Schuurman H-J, Pally C, Weckbecker G, Schuler W, Bruns C. SDZ RAD inhibits cold ischemia-induced vascular remodeling. Transplant Proc 1999; 31: 1024-1025
4. Neumayer H-H. Introducing everolimus (Certican®) in organ transplantation: An overview of preclinical and early clinical developments. Transplantation 2005; 79: S72-S75
5. Eisen HJ, Tuzcu EM, Dorent R et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 2003; 349: 847-858
6. Mancini D, Viganò M, Pulpon LA et al. 24-month results of a multicenter study of everolimus for the prevention of allograft rejection and vasculopathy in de novo cardiac transplant recipients. Poster presented at the American Transplant Congress, Washington, DC, USA: 2003
7. Kobashigawa J, Hare J, Eisen H et al. Everolimus in cardiac transplantation: 48 month results. Presented at the American Transplant Congress, Seattle, WA, USA: 2005
8. Eisen H, Starling RC, Kobashigawa J. Incidence of MACE and economic burden in de novo heart transplant patients: A 4-year comparison of everolimus and azathioprine. Transplant Int 2005; 18: PO-111
9. Lehmkuhl H, Dandel M, Hiemann N et al. 1-year single center clinical experience with everolimus (Certican®) in de novo heart transplant recipients. Submitted to Transplantation 2006
10. Lehmkuhl H, Hetzer R. Clinical experience with Certican® (everolimus) in de novo heart transplant patients at the Deutsches Herzzentrum Berlin. J Heart Lung Transplant 2005; 24 [Suppl 4]: S201-S205
11. Zuckermann A. Clinical experience with Certican® (everolimus) in maintenance heart transplant patients at the Medical University of Vienna. J Heart Lung Transplant 2005; 24 [Suppl 4]: S206-S209
12. Aranda JM,Jr, Hill J. Cardiac transplant vasculopathy. Chest 2000; 118: 1792-1800
13. Kapadia SR, Nissen SE, Tuzcu EM. Impact of intravascular ultrasound in understanding transplant coronary artery disease. Curr Opin Cardiol 1999; 14: 140-150
14. Kobashigawa JA, Tobis JM, Starling RC et al. Multicenter intravascular ultrasound validation study among heart transplant recipients: Outcomes after five years. J Am Coll Cardiol 2005; 45: 1532-1537
15. HCUPnet. Healthcare Cost and Utilization Project. http://hcup.ahrq.gov/ 2002
16. Massy ZA. Hyperlipidemia and cardiovascular disease after organ transplantation. Transplantation 2001; 72: S13-S15
17. Marcén R, Morales JM, Fernández-Juárez G et al. Risk factors of ischemic heart disease after renal transplantation. Transplant Proc 2002; 34: 394-395
18. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998; 32: S112-S119
19. Pascual J, Boletis I, Campistol JM. Everolimus (Certican®) in renal transplantation: A review of clinical trial data, current usage and future directions. Transplantation Rev 2006; 20: 1-18
20. Pascual J, Marcén R, Ortuño J. Clinical experience with everolimus (Certican®): Optimizing dose and tolerability. Transplantation 2005; 79: S80-S84
21. Pascual J. Concentration-controlled everolimus (Certican®): Combination with reduced dose calcineurin inhibitors. Transplantation 2005; 79: S76-S79
22. Vítko S, Margreiter R, Weimar W et al. Three-year efficacy and safety results from a study of everolimus versus mycophenolate mofetil in de novo renal transplant patients. Am J Transplant 2005; 5: 2521-2530
23. Lorber MI, Mulgaonkar S, Butt KMH et al. Everolimus versus mycophenolate mofetil in the prevention of rejection in de novo renal transplant recipients: A 3-year randomized, multicenter, phase III study. Transplantation 2005; 80: 244-252
24. Lehmkuhl H, Ross H, Eisen H, Valantine H. Everolimus (Certican®) in heart transplantation - optimizing renal function through minimizing cyclosporine exposure. Transplant Proc 2005; 37: 4145-4149
25. Vitko S, Tedesco H, Eris J et al. Everolimus with optimized cyclosporine dosing in renal transplant recipient: 6-month safety and efficacy results of two randomized studies. Am J Transplant 2004; 4: 626-635
26. Nashan B, Curtis J, Ponticelli C, Mourad G, Jaffe J, Haas T. Everolimus and reduced-exposure cyclosporine in de novo renal-transplant recipients: A three-year phase II, randomized, multicenter, open-label study. Transplantation 2004; 78: 1332-1340